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Purpose: The aim of this study is to assess results of treatment, factors inﬂuencing prognosis
with regard to causes of failure and treatment tolerance in patients with thymoma.
Material and methods: Between 1966 and 2006, 63 patients with thymoma had been treated
at the Centre of Oncology in Krakow. Patients were treated by means of different treatment
modalities: surgery followed by radiotherapy (52%), radiotherapy alone (13%), chemoradio-
therapy alone (15%), surgery followed by chemoradiotherapy (5%), surgery alone (5%) and
others.
Results: The 10-year locoregional recurrence-free survival (LRRFS) was 79%, disease free
survival (DFS) was 57% and overall survival (OS) was 57%. Masaoka stage was the only
independent prognostic factor for LRRFS. Masaoka stage and method of radiotherapy deliv-
ery (higher photon energies), were independent prognostic factors for OS. For DFS, the
independent prognostic factors were age, type of treatment (favoured surgery followed by
radiotherapy or chemoradiotherapy), Masaoka stage and year of start of treatment. Most
common reactions were lung ﬁbrosis in 36% of patients (mainly asymptomatic in mostpatients), pneumonitis (9%) and oesophagitis (4%).
Conclusions: Surgery combined with radiotherapy and chemoradiotherapy and modern
radiotherapy techniques are correlated with improvement of survival in patients with early
stage thymoma.
ie Ce© 2009 Wielkopolsk
. Introduction
hymomas, which originate from epithelial cells of the thy-
us, are the most common tumours of the anterosuperior
ediastinum and represent about 20–30% of all malignant
ediastinal tumours.1,2 These tumours are rare neoplasms;
he age-standardized incidence rates range from 0.1 to
.5 per 100 000 population annually in different countries.3
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Data regarding incidence of thymomas in Poland are not
available.
Usually thymomas are asymptomatic (the tumour is
detected by incidental chest X-rays) or associated with symp-
toms such as myasthenia gravis. The Masaoka classiﬁcationf Oncology, Maria Skłodowska-Curie, Memorial Institute, Krakow
x: +48 12 422 66 80.
has been the most widely used staging system.4,5
Due to the low incidence of these tumours (which pre-
cludes large randomized trials), little is known about optimal
evidence-based therapy of thymomas.
Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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Table 1 – Characteristics of patients.
Characteristics n %
Age
Median 43
Range 17–74
Gender
Female 32 51%
Male 31 49%
Symptoms before treatment
Absent 18 29%
Present 45 71%
Stage (Masaoka)
I 8 13%
IIa 4 6%
IIb 6 10%
IIIa 18 29%
IIIb 19 30%
IVa 4 6%
IVb 2 3%
Not applicable 2 3%
Type of treatment
Surgery followed by radiotherapy 33 52%
Radiotherapy alone 8 13%
Chemotherapy 2 3%
Chemoradiotherapy 9 14%
Palliative care 1 2%
Surgery 3 5%
Surgery followed by chemoradiotherapy 5 8%
Surgery followed by chemotherapy 2 3%
Completeness of operation
R0 16 37%
R1 4 9%
R2 14 33%
Not applicable 9 29%
Surgery still remains the principal method of treatment
of resectable thymomas, whereas adjuvant or neoadjuvant
radiotherapy plays an important role in subtotally resected
and unresectable cases.1,6,7 In advanced cases (Masaoka
stages III and IV) or in patients with recurrence after the
treatment, chemotherapy can prolong survival and offers
palliation. Advanced thymomas should be treated by a mul-
tidisciplinary team including surgeons, and medical and
radiation oncologists.8
The aim of this study is to assess the results of treatment
in patients with thymoma, factors inﬂuencing prognosis with
regard to causes of failure and treatment tolerance.
2. Materials and methods
Retrospective analysiswas performed in a group of 63 patients
with thymoma, who had been treated at the Centre of Oncol-
ogy in Krakow between 1966 and 2006. Characteristics of
patients are shown in Table 1. Median age was 43 years, 31
patients were males, 32 were females. About 70% of patients
were in stages III and IV. The majority (71%) of patients pre-
sented symptoms preceding diagnosis of thymomas; the most
common were chest pain with dyspnoea, ﬂu-like symptoms
and myasthenia gravis. In all cases diagnosis was conﬁrmed
by histology.diotherapy 1 5 ( 2 0 1 0 ) 15–20
Patients were treated using different treatment modalities:
surgery followed by radiotherapy (52%), radiotherapy alone
(13%), chemoradiotherapy alone (15%), surgery followed by
chemoradiotherapy (5%), surgery alone (5%) and others.
Median radiation dose was 4600 cGy (range 3000–7000) in
23 fractions (median). Radiotherapy was delivered by lin-
ear accelerator (37pts), cobalt (18pts) and ortovoltage (1pts)
because of development of methods of radiotherapy delivery
technologies during the 40 years of this retrospective analysis.
Indications for irradiation in our hospital were: subtotally
resected, all Masaoka stages II and III in adjuvant setting, and
unresectable thymoma.
Techniques of radiation delivery have changed during the
40 years of this analysis. Irradiated volume included whole
thymus, tumour bed, mediastinum. Two antero-posterior ﬁeld
techniques were used in the ﬁrst phase of treatment. Dose
to the spinal cord was limited to 45Gy using two or three
oblique ﬁelds in the second phase. The majority (60%) of
patients treated with chemotherapy received anthracycline-
and cisplatin-based regimens. All of them were treated in the
adjuvant setting.
In the radiochemotherapy subgroup patients subsequently
received nitrogranulogen (3 patients) or anthracycline-based
chemotherapy (6 patients).
2.1. Statistical methods
The main endpoints of the analysis were locoregional
recurrence-free survival (LRRFS), disease-free survival (DFS)
and overall survival (OS) rates.
Survival was measured from the date of diagnosis to the
date of death or last follow-up.
Locoregional recurrence-free survival was measured from
the date of treatment to the date of locoregional recurrence or
death or last follow-up in the subgroup of patients after com-
plete resection (conﬁrmed in imaging studies) and patients
treated with other modalities with complete response.
Time to progression was measured from the date of the
end of treatment to the date of local or distant progres-
sion. Local failure was deﬁned as failure occurring inside the
mediastinum (and/or with invasive growth into neighbouring
organs) and distant failure as any site of failure outside the
mediastinum.
Kaplan–Meier method was used to calculate survival rates.
Univariate and multivariate analyses of prognostic factors
were performed using log rank and Cox’s proportional haz-
ard method. In analyses of prognostic factors, clinical factors
(sex, age, stage, grade, histological type, symptoms, etc.) and
treatment factors (method of resection, completeness, radi-
ation dose, total treatment time, year of start of treatment)
were compared. P-Values of less than 0.05 were considered to
indicate statistical signiﬁcance.
3. Results3.1. Survival
During a median follow-up of 90 months (range 3–361), we
observed 22 cancer-related deaths and 11 patients died from
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Table 2 – Univariate analysis of prognostic factors (signiﬁcant bolded).
Prognostic factors Number of pts. % 10-Year LRFS% 10-Year DFS% 10-Year OS%
Total group 63 100% 79% 57% 57%
Gender
Female 32 51% 78% 56% 56%
Male 31 49% 79% 57% 58%
Age P=0.007
>43 years 33 52% 79% 72% 67%
≤43 years 30 48% 78% 41% 47%
Histological subtype (Bernatz classiﬁcation)
Not applicable 33 53% 71% 43% 44%
Epithelialthymoma 8 13% 100% 66% 50%
Lymphocytic thymoma 4 6% 100% 75% 75%
Mixed thymoma 11 17% 87.5% 67.5% 80%
Spindlecell thymoma 2 3% 100% 100% 100%
Thymic carcinoma 5 8% 0% 50% 40%
Symptoms before treatment
Absent 18 29% 85% 74% 81%
Present 45 71% 74% 49% 47%
Symptoms (described)
Myasthenia gravis 9 14% 50% 50% 52%
Chest pain, dyspnoea 23 36% 77% 53% 52%
Cough 2 3% 100% 100% 50%
Hoarseness 1 1.5% NA 0% 0%
Dysphagia 1 1.5% NA NA NA
Fatigue 1 1.5% NA NA NA
Flu-like symptoms 8 12.5% NA 22% 42%
Type of treatment P=0.03 P=0.002
Surgery followed by radiotherapy 33 52% 87% 81% 77%
Radiotherapy alone 8 13% 66% 39% 25%
Chemotherapy 2 3% NA 0% 0%
Chemoradiotherapy 10 15% 0% 0% 0%
Surgery 3 5% 100% 100% 100%
Surgery followed by chemoradiotherapy 5 8% 0% 0% 80%
Surgery followed by chemotherapy 2 3% 100% 0% 50%
Completeness of operation P=0.04 P=0.03 P=0.001
R0 16 37% 100% 91% 100%
R1 4 9% 100% NA 75%
R2 14 33% 73% 47% 71%
No data 9 29% 59% 35% 27%
Masaoka stage P=0.04 P=0.02 P=0.004
I 8 13% 100% 83% 100%
IIa 4 6% NA NA 100%
IIb 6 10% NA NA 100%
IIIa 18 29% 83% 65% 71%
IIIb 19 30% 42% 23% 28%
IVa 4 6% 0% 0% 0%
IVb 2 3% NA NA 0%
No data 2 3% NA 0% 0%
Radiotherapy P=0.04 P=0.001
Without radiotherapy 7 11.1% NA 33% 33%
Ortovoltage 1 1.6% NA 0% 0%
Cobalt 18 28.6% 80% 58% 35%
Linear accelerator 37 58.7% 73% 57% 73%
Year of start of treatment P=0.01 P=0.005
1966–1991 31 49% 81% 50% 42%
1992–2006 32 51% 71% 62% 74%
Radiation dose
Without radiotherapy 7 11.1%
<4600 27 42.9% 84% 58% 53%
≥4600 29 46% 63% 52% 59%
NA, not applicable.
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other causes. About half of patients (30)were alive inMay 2007,
of whom 24 were disease free.
The 10-year LRRFS rate, DFS rate and OS (Fig. 1) rate were
79, 57 and 57%, respectively.
The univariate analysis (Table 2) showed that complete-
ness of operation and Masaoka stage had a signiﬁcant impact
on LRRFS. LRRFS in the subgroup of patients after complete
resection (conﬁrmed in imaging studies) and patients treated
with other modalities with complete response were 86 and
66%, respectively (P=0.2).
The following prognostic factors signiﬁcantly inﬂuenced
DFS: age, type of treatment, completeness of operation,
Masaoka stage, method of radiotherapy delivery and year of
start of treatment.
Type of treatment, completeness of operation, Masaoka
stage, year of start of treatment and method of radiotherapy
deliverywere statistically signiﬁcant prognostic factors for OS.
Masaoka stage was the only independent prognostic fac-
tor for LRRFS (Table 3). The risk of locoregional recurrence in
patients with early Masaoka stages was less than half of the
risk in advanced stage patients.
Table 3 – 10 Years multivariate analysis of prognostic
factors.
Variable Relative risk P-Value
LRFS Masaoka stage 1.8 0.004
DFS
Age 0.91 0.00069
Type of treatment 1.78 0.000199
Masaoka stage 1.56 0.0088
Year of start of treatment 0.16 0.04
OS
Masaoka stage 2.10 0.0000
Radiotherapy 0.43 0.0006l survival.
In the multivariate analysis, the following prognostic fac-
tors had a statistically signiﬁcant impact on recurrence rate:
age (favoured older patients), type of treatment, Masaoka
stage (favoured early stage patients) and year of start of treat-
ment (favoured patients treated after 1991) (Table 3).
For OS (Table 3), the independent prognostic factors were
Masaoka stage and method of radiotherapy delivery (higher
photon energies). The risk of death was more than two times
higher in advanced Masaoka stage patients and in those who
were treatedwith oldermethods of radiotherapydelivery. Ten-
year OS was 100, 100, 71, 28 and 0% in stages I, II, IIIA, IIIB and
IV, respectively.
Neither symptoms (myasthenia gravis, chest pain, dysp-
noea) nor radiotherapy dose, irradiated volume, or histological
stage appeared to be of prognostic signiﬁcance in this group
of patients.
In 25 patients treated with chemoradiotherapy, radiother-
apy, chemotherapy or surgery (in the case of macroscopically
non-radical operation) follow-up imaging studies revealed
complete response in 9 patients, partial response in 2, stable
disease in 6 and progressive disease in 8.3.2. Analysis of failure
During the follow-up, local recurrence of malignancy was
observed in 8 patients; half of them were located outside the
Table 4 – Treatment complications (number of patients).
Complication EORTC/RTOG scale
I II III/IV
Lung ﬁbrosis 11 8 1
Pneumonitis 2 2 1
Oesophagitis 0 2 0
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rradiated volume. In 16 patients distant failure was observed.
n 8 cases (58%) distant failure was located in the lungs, in 3
36%) it was found in the liver, and in 2 in the brain. Median
ime to distant recurrence was 18 months (6–76).
.3. Safety
adiation therapy was well tolerated in 55% of patients (31 of
6 radiotherapy patients). The most common reactions were
ung ﬁbrosis in 36% of patients (asymptomatic in the majority
f patients), pneumonitis (9%) and oesophagitis (4%).
There were two serious (grade 3) side effects: lung ﬁbro-
is and oesophagitis. Severities of the reactions are shown in
able 4. Incidence of reactions was correlated with age and
otal dose. Patients who complained of reactions were older
48 years vs 40 years) and were irradiated with a higher dose
median 4868 cGy vs 4283 cGy) compared to asymptomatic
atients.
Four patients (6%) had a secondary malignancy (NHL,
alignant melanoma, breast cancer, non-small lung cancer).
ll secondary tumours were diagnosed later than thymoma
7–190 months). The patients with second malignancy pre-
ented more advanced thymoma than patients without
econdaries (P=0.037). No statistically signiﬁcant differences
ere demonstrated in other variables: age, gender, type of
reatment, radiotherapy dose, radiotherapy volume, histolog-
cal type and symptoms.
. Discussion
he low incidence of thymomas precludes conducting
rospective trials and evidence is based on small retrospec-
ive studies with moderate numbers of included patients.
e found only one randomized control trial of thymoma
reatment.9 There are also no thymoma treatment practice
uidelines.
The retrospective design is a limitation of the study. Over
he 40 years of observation there have beenmany changes and
mprovements of both diagnostics and therapy. Due to the low
atient number it is difﬁcult to perform adequate subgroup
nalysis.
Clinical characteristics of our series of patients are similar
o those reported in the literature. Sex distribution was bal-
nced and most patients were in the ﬁfth decade of life.3,7
ncidence of symptoms most commonly reported by the lit-
rature – chest pain, dyspnoea (36%) and myasthenia gravis
14%) – were lower than reported in other series, which may
e inﬂuenced by interviewer bias, typical for retrospective
ethodology.2,10,11,12
Overall survival rates for stages I, II and IIIa are higher
hereas for stages IIIB and IV are lower than reported
lsewhere.10,11,13 Survival for thewhole groupof patients (57%)
s lower than in other series due to the fact that about 70%were
dvanced (Masaoka stages III and IV), while in the literature
0% are diagnosed when they are localised within the capsule
nd do not inﬁltrate.7
With respect to prognosis in our series Masaoka stage was
prognostic factor of LRRFS, DFS and OS.11,13–17 Patients who
tarted treatment after 1991 had fewer recurrences than thoseiotherapy 1 5 ( 2 0 1 0 ) 15–20 19
who were treated earlier. This could be explained by the fact
of improvement of imaging and radiation delivery methods
and the common introduction of anthracyclines into adjuvant
treatment. Patients older than 43 had longer DFS, which could
be attributed to aggressiveness (histological grade). Neverthe-
less, this observation is opposite to the majority of results
published in other series (with the exception of Resbeut’s
study).2,11,13,18
In contrast, patient sex, histological subtype and presence
of myasthenia gravis and radiotherapy dose show no correla-
tion with survival, which is consistent with the ﬁndings of a
number of published studies.2,13
During 40 years ﬁve different classiﬁcations were pro-
posed by Bernatz, Rosai and Levine, Müller and Hermelink,
Suster and Moran, and the WHO, which still seem to be
controversial.19,20 In our group of patients the Bernatz classiﬁ-
cation was used most often (47%). Nevertheless, a comparison
could not be performed, which is a limitation of our study.
Surgical margin status was not an independent prognostic
factor in multivariate analysis (only in univariate), unlike in
other series.17,21
In our series distant relapses are two times more common
than local ones, which can be explained by low sensitivity
and speciﬁcity of detection of local recurrence (frequently
asymptomatic and later can lead to distant failure) and higher
number of patients with advanced disease compared to other
series.2
In 25 patients treated with chemoradiotherapy, radiother-
apy, chemotherapy or surgery (in the case of macroscopically
non-radical operation) response rate assessed by follow-up
imaging studies was 44%, whereas in other studies it is het-
erogeneous and ranges between 24 and 100%.22,23
Radiotherapywaswell tolerated in themajority of patients.
Most reactions were asymptomatic. The frequency and sever-
ity of complications of both chemotherapy and radiotherapy
was low; nevertheless, this result should be interpreted with
caution because of underreporting of side effects in retrospec-
tive studies.
An increased risk of developing secondary malignancy has
been suspected in thymoma, with a reported incidence from 3
to 22%.24 Reported incidence of secondary malignancies is 6%,
which correlates with Masaoka stage only. No other studied
factor inﬂuenced incidence of secondaries.
5. Conclusions
Surgery combined with radiotherapy and chemoradiother-
apy and modern radiotherapy techniques (three-dimensional
treatment planning, CT imaging, higher photon energies) are
correlatedwith improvement of survival in patientswith early
stage thymoma. In patients with very early stage thymoma,
complete surgical excision seems to be a sufﬁcient method of
treatment.
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